ArticleNature2026
Identification of cross-stage, cross-species malaria CD8
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
40 authors.
Camila R R Barbosa *Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Luna B de Lacerda *Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.ORCID http://orcid.org/0000-0003-1577-348X
Paulo J G Bettencourt *Jenner Institute, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-4884-5470
David MorrowVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.ORCID http://orcid.org/0000-0003-4686-830X
Dhelio B PereiraCentro de Pesquisas em Medicina Tropical de Rondônia, Porto Velho, Brazil.ORCID http://orcid.org/0000-0002-7761-5498
Maya AleshnickVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Julie L MitchellVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.ORCID http://orcid.org/0000-0001-7400-7027
Nicholas C PoultonLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Cristopher GomesInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.ORCID http://orcid.org/0000-0002-4228-393X
Lídia P B CordeiroInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Kadia DoumbiaParasites and Microbes Research and Training Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Christina NtallaMax Planck Institute for Infection Biology, Berlin, Germany.
Charles AramaParasites and Microbes Research and Training Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.ORCID http://orcid.org/0000-0002-8255-6533
Zezhou ZhaoRagon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4792-6073
Guilherme C MaiaInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Gregório G AlmeidaInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Marie Rose SchrimpfInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Thalia F HartVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Derek HaumpyVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.ORCID http://orcid.org/0009-0007-1972-0656
Beatriz C Medeiros-RodriguesInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.ORCID http://orcid.org/0009-0002-3622-6848
Camila M CostaInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Annalisa NicastriJenner Institute, University of Oxford, Oxford, UK.
Roxanne M GilbrideVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
John B SchellVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.ORCID http://orcid.org/0000-0001-6707-7051
Payton KirtleyVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Lis R V AntonelliInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Gaurav D GaihaRagon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6875-4472
Scott G HansenVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Judy LiebermanProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6200-4715
Ricardo T GazzinelliInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Moussa NiangalyParasites and Microbes Research and Training Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
John WoodfordLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Joel GoldbergLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Klaus FrühVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.ORCID http://orcid.org/0000-0001-8014-3877
Silvia PortugalMax Planck Institute for Infection Biology, Berlin, Germany.ORCID http://orcid.org/0000-0003-4567-9101
Patrick E DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4483-5005
Nicola TernetteJenner Institute, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-9283-0743
Brandon WilderVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA. wilderb@ohsu.edu.ORCID http://orcid.org/0000-0002-5577-7787
Adrian V S HillJenner Institute, University of Oxford, Oxford, UK. adrian.hill@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0003-0900-9629
Caroline JunqueiraInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil. caroline.junqueira@irb.usi.ch.ORCID http://orcid.org/0000-0003-0545-0986
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MNIH HHS P51 OD011092
Abstract
A major limitation on the development of a malaria vaccine is the lack of validated T cell epitope targets. Plasmodium falciparum is the most prevalent malaria parasite affecting humans in Africa, whereas Plasmodium vivax is more widespread and is the main species that causes malaria in the Americas and Asia
Indexed as
Antigens, ProtozoanCD8-Positive T-LymphocytesMalariaPlasmodium falciparumPlasmodium vivaxAllelesAnimalsAntigen PresentationCross ReactionsEpitopes, T-LymphocyteHistocompatibility Antigens Class IHumansLife Cycle StagesMalaria, FalciparumMalaria VaccinesMalaria, VivaxAntigens, ProtozoanEpitopes, T-LymphocyteHistocompatibility Antigens Class IMalaria Vaccines
Identifiers
PMID
42386975What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.